Veradermics, Incorporated
MANE
Positions held
Your positionsMANE isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Veradermics, Incorporated operates in the biotechnology sector, which is characterized by rapid innovation and significant growth potential, particularly in developing new therapies and treatments.
- The company's market cap stands at approximately $4.55 billion, indicating strong investor interest and confidence.
- Veradermics has a strong buy recommendation with a score of 44.00, reflecting positive trends in technical indicators.
- Despite its potential, Veradermics has not generated revenue, which raises concerns about its viability and ability to sustain operations.
- The company reported a net income loss of $69.995 million for the year 2025, highlighting ongoing financial struggles.
- In the most recent quarter, 2026-Q2, the net income loss was $23.502 million, indicating a continued trend of negative financial performance.
Fundamentals
| Market cap | $5.29B | Enterprise value | $4.47B | Trailing P/E | — | Forward P/E | -47.12 |
| PEG | — | Price / book | 6.50 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.00 |
| Current ratio | 70.53 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $163.50 |
| 52w high | $136.72 | 52w low | $32.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$23.5M | -$27.2M | -$21.8M | -$20.1M | -$15.6M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$29.6M | -$29.7M | -$22.8M | -$19.8M | -$16.1M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — |
| Net income | -$70.0M | -$26.5M | -$16.5M |
| Gross margin | — | — | — |
| Gross profit | — | — | — |
| Operating income | -$71.6M | -$26.4M | -$17.3M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-12 · Baldness Drug Stocks like Veradermics (MANE) and Absci (ABSI) Are Chasing the Same Wall Street Magic as Ozempic
2026-09-03 · Veradermics to Present at Upcoming September Investor Conferences
2026-09-03 · Veradermics (MANE) Stock Looks Overvalued After Its 161% Rally
2026-09-02 · Is Veradermics (MANE) Still Undervalued After Its 161% Year To Date Run?
2026-08-31 · Hair Loss Biotechs Emerge As Wall Street's Newest Growth Trade
2026-08-17 · Veradermics Insider Sold Shares Worth $10,711,700, According to a Recent SEC Filing
2026-08-11 · Veradermics: Q2 Earnings Snapshot
2026-08-11 · Veradermics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
2026-08-04 · Veradermics (MANE) Positioned to Disrupt Hair Loss Market
2026-07-19 · Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
2026-07-15 · Veradermics Hair Loss Pill Shows Strong Phase II Signal in Women
Price (daily)
Full chart · RSI · MACD · patterns